Эффективность и безопасность пищевых добавок в лечении психических расстройств: мета-обзор мета-анализов рандомизированных контролируемых исследований
Всемирная психиатрия. №3 2019
Эффективность и безопасность пищевых добавок в лечении психических расстройств: мета-обзор мета-анализов рандомизированных контролируемых исследований
Joseph Firth1-3, Scott B.Teasdale4,5, Kelly Allott3,6, Dan Siskind7,8, Wolfgang Marx9, Jack Cotter10, Nicola Veronese11,12, Felipe Schuch13, Lee Smith14, Marco Solmi15,16, André F. Carvalho17,18, Davy Vancampfort19,20, Michael Berk6,9, Brendon Stubbs21,22, Jerome Sarris1,23
1NICM Health Research Institute, Western Sydney University, Westmead, Australia; 2Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, Uni- versity of Manchester, Manchester, UK; 3Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia; 4School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia; 5Keeping the Body in Mind Program, South Eastern Sydney Local Health District, Sydney, Australia; 6Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia; 7Metro South Addiction and Mental Health Service, Brisbane, Australia; 8School of Medicine, University of Queensland, Brisbane, Australia; 9IMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Australia; 10Cambridge Cognition, Cambridge, UK; 11Neurosci- ence Institute, National Research Council, Padua, Italy; 12Research Hospital, National Institute of Gastroenterology, IRCCS De Bellis, Castellana Grotte, Bari, Italy; 13Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil; 14Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK; 15Department of Neurosciences, University of Padua, Padua, Italy; 16Padua Neuroscience Center, University of Padua, Padua, Italy; 17Centre for Addiction and Mental Health, Toronto, ON, Canada; 18Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 19KU Leuven Department of Rehabilitation Sciences, Leuven, Belgium; 20University Psychiatric Centre KU Leuven, Kortenberg, Belgium; 21South London and Maudsley NHS Foundation Trust, London, UK; 22Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 23Professional Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, Australia
Стр. 317-332
1335 просмотров
Опубликовано: 24 октября 2019
Аннотация / Abstract
a:2:{s:4:"TEXT";s:65521:"a:2:{s:4:"TYPE";s:4:"HTML";s:4:"TEXT";s:102634:"Перевод: Симонов Р.В. (Санкт-Петербург)
Редактура: к.м.н. Чумаков Е.М. (Санкт-Петербург)
Firth J, Teasdale SB, Allott K. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(3):308–24.
Роль питания в психическом здоровье становится все более признанной. Наряду с обычным приемом пищи, рацион питания также может включать «пищевые добавки», среди которых полиненасыщенные жирные кислоты (ПНЖК), витамины, минералы, антиоксиданты, аминокислоты и пре/пробиотики. В последнее время появилось большое количество мета-анализов изучения пищевых добавок при лечении психических расстройств. Чтобы подготовить мета-обзор этих важнейших данных, мы собрали и оценили все мета-анализы рандомизированных контролируемых исследований (РКТ), в которых сообщается об эффективности и безопасности пищевых добавок при частых и тяжелых психических расстройствах. Наш системный поиск выявил 33 мета-анализа плацебо-контролируемых РКТ с первичным анализом, включающих данные о результатах о 10951 человек. Наиболее убедительные доказательства были найдены в отношении ПНЖК (особенно эйкозапентаеновой кислоты) при использовании в качестве дополнительного средства в лечении депрессии. Более новые данные свидетельствуют о том, что ПНЖК также могут быть полезны при синдроме дефицита внимания/гиперактивности, в то время как доказательств эффективности при лечении шизофрении не получено. Добавки на основе фолата широко исследовались как адъювантная терапия при лечении депрессии и шизофрении, с положительным эффектом при высоких дозах метилфолата в РКТ при лечении большого депрессивного расстройства. Появились новые данные в пользу того, что N-ацетилцистеин является полезным вспомогательным средством при расстройствах настроения и шизофрении. Все пищевые добавки имели хорошие профили безопасности, без признак...
Перевод: Симонов Р.В. (Санкт-Петербург)
Редактура: к.м.н. Чумаков Е.М. (Санкт-Петербург)
Firth J, Teasdale SB, Allott K. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(3):308–24.
Роль питания в психическом здоровье становится все более признанной. Наряду с обычным приемом пищи, рацион питания также может включать «пищевые добавки», среди которых полиненасыщенные жирные кислоты (ПНЖК), витамины, минералы, антиоксиданты, аминокислоты и пре/пробиотики. В последнее время появилось большое количество мета-анализов изучения пищевых добавок при лечении психических расстройств. Чтобы подготовить мета-обзор этих важнейших данных, мы собрали и оценили все мета-анализы рандомизированных контролируемых исследований (РКТ), в которых сообщается об эффективности и безопасности пищевых до...
Материал для специалистов
Полный текст статьи доступен только зарегистрированным пользователям.
Вход / Регистрация- 1. Firth J, Stubbs B, Teasdale SB et al. Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 2018;17:365-7.
- 2. Teasdale SB, Ward PB, Samaras K et al. Dietary intake of people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2019; 214:251-9.
- 3. van den Berk-Clark C, Secrest S, Walls J et al. Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: a systematic review and meta-analysis. Health Psychol 2018;37:407-16.
- 4. Woo H, Kim D, Hong Y-S et al. Dietary patterns in children with attention deficit/hyperactivity disorder (ADHD). Nutrients 2014;6:1539-53.
- 5. Howard AL, Robinson M, Smith GJ et al. ADHD is associated with a “Western” dietary pattern in adolescents. J Atten Disord 2011;15:
- 403-11.
- 6. Jacka FN, Cherbuin N, Anstey KJ et al. Does reverse causality explain the relationship between diet and depression? J Affect Disord 2015;175:248-50.
- 7. Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur Neuropsychopharmacol 2016; 26:1673-7.
- 8. Firth J, Teasdale SB, Jackson SE et al. Do reductions in ghrelin contribute towards antipsychotic-induced weight gain? Schizophr Res (in press).
- 9. Tolkien K, Bradburn S, Murgatroyd C. An anti-inflammatory diet as a potential intervention for depressive disorders: a systematic review and meta-analysis. Clin Nutr (in press).
- 10. Lassale C, Batty GD, Baghdadli A et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Mol Psychiatry 2019;24:965-86.
- 11. Firth J, Carney R, Stubbs B et al. Nutritional deficiencies and clinical correlates in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull 2018;44:1275-92.
- 12. Swinburn BA, Kraak VI, Allender S et al. The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report. Lancet 2019;393:791-846.
- 13. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019;393:1958-72.
- 14. Sarris J, Logan AC, Akbaraly TN et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry 2015;2:271-4.World Psychiatry 18:3– October 2019 323
- 15. Sarris J, Logan AC, Akbaraly TN et al. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry 2015;14:370-1.
- 16. Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr 2000;71:1669S-73S.
- 17. Kantor ED, Rehm CD, Du M et al. Trends in dietary supplement use among US adults from 1999-2012. JAMA 2016;316:1464-74.
- 18. Wactawski-Wende J, Kotchen JM, Anderson GL et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:684-96.
- 19. Jenkins DJ, Spence JD, Giovannucci EL et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol 2018;71: 2570-84.
- 20. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47.
- 21. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr 2007;85:285S-8S.
- 22. Lederle FA. Oral cobalamin for pernicious anemia: medicine’s best kept secret? JAMA 1991;265: 94-5.
- 23. Ala A, Walker AP, Ashkan K et al. Wilson’s disease. Lancet 2007;369:397- 408.
- 24. Siscovick DS, Barringer TA, Fretts AM et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 2017;135:e867-84.
- 25. Berk M, Jacka FN. Diet and depression – from confirmation to implementation. JAMA 2019;321:842-3.
- 26. Berk M, Williams LJ, Jacka FN et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.
- 27. Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-71.
- 28. Berk M, Kapczinski F, Andreazza A et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:
- 804-17.
- 29. Irwin MR, Piber D. Insomnia and inflammation: a two hit model of depression risk and prevention. World Psychiatry 2018;17:359-61.
- 30. Köhler CA, Freitas TH, Stubbs B et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 2018;55:4195-4206.
- 31. Schuch FB, Deslandes AC, Stubbs B et al. Neurobiological effects of exercise on major depressive disorder: a systematic review. Neurosci Biobehav Rev 2016;61:1-11.
- 32. Dodd S, Dean O, Copolov DL et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008;8:1955-62.
- 33. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505.
- 34. Swardfager W, Herrmann N, Mazereeuw G et al. Zinc in depression: a meta-analysis. Biol Psychiatry 2013;74:872-8.
- 35. Joe P, Petrilli M, Malaspina D et al. Zinc in schizophrenia: a meta-analysis. Gen Hosp Psychiatry 2018;53:19-24.
- 36. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Commun Health 2007;61:631-7.
- 37. Belbasis L, Kohler CA, Stefanis N et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand 2018;137:88-97.
- 38. Anglin RES, Samaan Z, Walter SD et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013;202:100-7.
- 39. Murri MB, Respino M, Masotti M et al. Vitamin D and psychosis: mini meta-analysis. Schizophr Res 2013;150:235-9.
- 40. Lally J, Ajnakina O, Singh N et al. Vitamin D and clinical symptoms in first episode psychosis (FEP): a prospective cohort study. Schizophr Res 2019;204:381-8.
- 41. Zheng P, Zeng B, Liu M et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv 2019;5:eaau8317.
- 42. Valles-Colomer M, Falony G, Darzi Y et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019;4:623-32.
- 43. Biesalski HK. Nutrition meets the microbiome: micronutrients and the microbiota. Ann NY Acad Sci 2016;1372:53-64.
- 44. Delzenne NM, Neyrinck AM, Bäckhed F et al. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011;7:639.
- 45. Dash S, Clarke G, Berk M et al. The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry 2015;28:1-6.
- 46. Kaplan BJ, Rucklidge JJ, Romijn A et al. The emerging field of nutritional mental health: inflammation, the microbiome, oxidative stress, and mitochondrial function. Clin Psychol Sci 2015;3:964-80.
- 47. Bot M, Brouwer IA, Roca M et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA 2019;321:858-68.
- 48. Freedman R, Hunter SK, Hoffman MC. Prenatal primary prevention of mental illness by micronutrient supplements in pregnancy. Am J Psychiatry 2018;175:607-19.
- 49. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
- 50. Shea BJ, Reeves BC, Wells G et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.
- 51. Hallahan B, Ryan T, Hibbeln JR et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2016;209:192- 201.
- 52. Bergman H, Walker DM, Nikolakopoulou A et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017;21:1-218.
- 53. Firth J, Stubbs B, Sarris J et al. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychol Med 2017;47:1515-27.
- 54. Sakuma K, Matsunaga S, Nomura I et al. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology 2018:235:2303-14.
- 55. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012;32:179-85.
- 56. Zheng W, Zhang QE, Cai DB et al. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2018;137:391-400.
- 57. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011;25:859- 85.
- 58. Siskind DJ, Lee M, Ravindran A et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 2018;52:751-67.
- 59. Grosso G, Pajak A, Marventano S et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014;9:e96905.
- 60. Davies C, Cipriani A, Ioannidis JPA et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry 2018;17:196-209.
- 61. Devoe DJ, Farris MS, Townes P et al. Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv Psychiatry 2019;13:3-17.
- 62. Devoe DJ, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull 2018;44:807-23.
- 63. Devoe DJ, Farris MS, Townes P et al. Interventions and social functioning in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv Psychiatry 2019;13:169-80.
- 64. Mocking RJ, Harmsen I, Assies J et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016;6:e756.
- 65. Schefft C, Kilarski LL, Bschor T et al. Efficacy of adding nutritional supplements in unipolar depression: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2017;27:1090-109.
- 66. Bae JH, Kim G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr Res 2018;50:1-9.
- 67. Roberts E, Carter B, Young AH. Caveat emptor: folate in unipolar depressive illness, a systematic review and meta-analysis. J Psychopharmacol 2018;32:377-84.
- 68. Mukai T, Kishi T, Matsuda Y et al. A meta-analysis of inositol for depressionand anxiety disorders. Hum Psychopharmacol 2014;29:55-63
- 69. Vellekkatt F, Menon V. Efficacy of vitamin D supplementation in major depression: a meta-analysis of randomized controlled trials. J Postgrad Med 2019;65:74-80.
- 70. Phelan D, Molero P, Martinez-Gonzalez MA et al. Magnesium and mood disorders: systematic review and meta-analysis. BJPsych Open 2018;4:167- 79.
- 71. Ng QX, Peters C, Ho CYX et al. A meta-analysis of the use of probiotics to alleviate depressive symptoms. J Affect Disord 2018;228:13-9.
- 72. Fernandes BS, Dean OM, Dodd S et al. N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry 2016;77:e457-e66.
- 73. Sarris J, Murphy J, Mischoulon D et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry 2016;173:575- 87.
- 74. Couto JP, Moreira R. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: a systematic review of the clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 2018;86:245-54.
- 75. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73:81-6.
- 76. Rosenblat JD, Kakar R, Berk M et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 2016;18:89-101.
- 77. Puri BK, Martins JG. Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2014;90:179-89.
- 78. Goode AP, Coeytaux RR, Maslow GR et al. Nonpharmacologic treatments for attention-deficit/hyperactivity disorder: a systematic review. Pediatrics 2018;141:e20180094.
- 79. Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014;34:496-505.
- 80. Cooper RE, Tye C, Kuntsi J et al. The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: a systematic review and meta-analysis. J Affect Disord 2016;190:474-82.
- 81. Chang JPC, Su KP, Mondelli V et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology 2018;43:534-45.
- 82. Cooper RE, Tye C, Kuntsi J et al. Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. J Psychopharmacol 2015;29:753-63.
- 83. Rapaport MH, Nierenberg AA, Schettler PJ et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 2016;21:71-9.
- 84. Jiang W, Whellan DJ, Adams KF et al. Long-chain omega-3 fatty acid supplements in depressed heart failure patients: results of the OCEAN trial. JACC Heart Fail 2018;6:833-43.
- 85. Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M et al. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016;73:34-44.
- 86. Robinson DG, Gallego JA, John M et al. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res 2019;204:295-303.
- 87. Pawełczyk T, Piatkowska-Janko E, Bogorodzki P et al. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: a secondary outcome analysis of the OFFER randomized controlled study. Schizophr Res 2018;195:168-75.
- 88. Firth J, Rosenbaum S, Ward PB et al. Adjunctive nutrients in first-episode psychosis: a systematic review of efficacy, tolerability and neurobiological mechanisms. Early Interv Psychiatry 2018;12:774-83.
- 89. Farah A. The role of L-methylfolate in depressive disorders. CNS Spectr 2009;14:2-7.
- 90. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry 2009;70:12-7.
- 91. Roffman JL, Petruzzi LJ, Tanner AS et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry 2018;23:316-22.
- 92. Kakar MS, Jehangir S, Mustafa M et al. Therapeutic efficacy of combination therapy of l-methylfolate and escitalopram in depression. Pak Armed Forces Med J 2017;67:976-81.
- 93. Rainka M, Aladeen T, Westphal E et al. L-methylfolate calcium in adolescents and children: a retrospective analysis. Presented at the Annual Meeting of the American Academy of Neurology, Los Angeles, April 2018.
- 94. Breier A, Liffick E, Hummer TA et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res 2018;199:395- 402.
- 95. Yolland CO, Phillipou A, Castle DJ et al. Improvement of cognitive function in schizophrenia with N-acetylcysteine: a theoretical review. Nutr Neurosci (in press).
- 96. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36:78-86.
- 97. Moghaddam B, Javitt DJN. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15.
- 98. Zhang HX, Hyrc K, Thio LL. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol 2009;587: 3207-20.
- 99. Slyepchenko A, Maes M, Jacka FN et al. Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother Psychosom 2017;86:31-46.
- 100. Zheng P, Zeng B, Zhou C et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry 2016;21:786-96.
- 101. Cheung SG, Goldenthal AR, Uhlemann A-C et al. Systematic review of gut microbiota and major depression. Front Psychiatry 2019;10:34.
- 102. Kao A, Safarikova J, Marquardt T et al. Pro-cognitive effect of a prebiotic in psychosis: a double blind placebo controlled cross-over study. Schizophr Res 2019;208:460-1.
- 103. Liu NH, Daumit GL, Dua T et al. Excess of mortality in person with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 2017;16:30-40.
- 104. Reedy J, Krebs-Smith SM, Miller PE et al. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr 2014;144:881-9.
- 105. Teasdale SB, Ward PB, Rosenbaum S et al. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 2017;210:110-8.
- 106. Firth J, Marx W, Dash S et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med 2019;8:265-80.
- 107. Rucklidge JJ, Kaplan BJ. Broad-spectrum micronutrient treatment for attention-deficit/hyperactivity disorder: rationale and evidence to date. CNS Drugs 2014;28:775-85.
- 108. Sarris J, Byrne GJ, Stough C et al. Nutraceuticals for major depressive disorder – more is not merrier: an 8-week double-blind, randomised, controlled trial. J Affect Disord 2019;245:1007-15.
- 109. Berk M, Turner A, Malhi GS et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med 2019;17:18.
- 110. Shelton RC, Pencina MJ, Barrentine LW et al. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry 2015;76:1635-41.
← Предыдущая статья
Влияние статуса национального меньшинства и социального контекста на развитие депрессии и тревоги: лонгитюдное исследование на примере молодежи пуэрториканского происхождения
Следующая статья →
Эффективность вмешательств, осуществляемых при помощи приложений для смартфонов, при решении проблем, связанных с психическим здоровьем: мета-анализ рандомизированных контролируемых исследований